Your browser doesn't support javascript.
Postexposure-vaccine-prophylaxis against COVID-19.
Shmuelian, Zohar; Warszawer, Yehuda; Or, Omri; Arbel-Alon, Sagit; Giladi, Hilla; Avgil Tsadok, Meytal; Cohen, Roy; Shefer, Galit; Shlomi, Dekel; Hoshen, Moshe; Maruotti, Antonello; Jona-Lasinio, Giovanna; Galun, Eithan.
  • Shmuelian Z; Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel.
  • Warszawer Y; Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel.
  • Or O; Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel.
  • Arbel-Alon S; The Ministry of Welfare and Social Affairs, Chief Physician, Government of Israel, Jerusalem, Israel.
  • Giladi H; Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel.
  • Avgil Tsadok M; TIMNA-Israel Ministry of Health's Big Data Platform, Ministry of Health, Jerusalem, Israel.
  • Cohen R; TIMNA-Israel Ministry of Health's Big Data Platform, Ministry of Health, Jerusalem, Israel.
  • Shefer G; TIMNA-Israel Ministry of Health's Big Data Platform, Ministry of Health, Jerusalem, Israel.
  • Shlomi D; Clalit Health Services Community Division, Ariel, Israel and the Pulmonary Clinic, Dan-Petah-Tiqwa District, Adelson School of Medicine, Ariel University, Ramat-Gan, Israel.
  • Hoshen M; Research Unit, Department of Bioinformatics, Dan-Petah-Tiqwa District, Clalit Health Services, Jerusalem College of Technology, Jerusalem, Israel.
  • Maruotti A; Department of Law, Economics, Politics and Modern Languages, Libera Università Maria SS Assunta, Rome, Italy.
  • Jona-Lasinio G; Department of Statistical Sciences, "Sapienza" University of Rome, Rome, Italy.
  • Galun E; Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel.
J Med Virol ; : e28274, 2022 Nov 02.
Article in English | MEDLINE | ID: covidwho-2235592
ABSTRACT
During the COVID-19 pandemic, postexposure-vaccine-prophylaxis is not a practice. Following exposure, only patient isolation is imposed. Moreover, no therapeutic prevention approach is applied. We asked whether evidence exists for reduced mortality rate following postexposure-vaccine-prophylaxis. To estimate the effectiveness of postexposure-vaccine-prophylaxis, we obtained data from the Israeli Ministry of Health registry. The study population consisted of Israeli residents aged 12 years and older, identified for the first time as PCR-positive for SARS-CoV-2, between December 20th, 2020 (the beginning of the vaccination campaign) and October 7th, 2021. We compared "recently injected" patients-that proved PCR-positive on the same day or on 1 of the 5 consecutive days after first vaccination (representing an unintended postexposure-vaccine-prophylaxis)s-to unvaccinated control group. Among Israeli residents identified PCR-positive for SARS-CoV-2, 11 687 were found positive on the day they received their first vaccine injection (BNT162b2) or on 1 of the 5 days thereafter. In patients over 65 years, 143 deaths occurred among 1412 recently injected (10.13%) compared to 255 deaths among the 1412 unvaccinated (18.06%), odd ratio (OR) 0.51 (95% confidence interval [CI] 0.41-0.64; p < 0.001). A significant reduction in the death toll was observed among the 55-64 age group, with 8 deaths occurring among the 1320 recently injected (0.61%) compared to 24 deaths among the 1320 unvaccinated control (1.82%), OR 0.33 (95% CI 0.13-0.76; p = 0.007). Postexposure-vaccine-prophylaxis is effective against death in COVID-19 infection.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.28274

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.28274